Bristol-Myers Squibb

Q1 2025 Results

• Bristol-Myers Squibb raised its full-year 2025 guidance to a revenue range of $45.8 billion to $46.8 billion and non-GAAP diluted earnings per share of $6.70 to $7.00.
• The company’s growth portfolio achieved a 16% year-over-year increase in net sales, driven by strong demand for Opdivo, Breyanzi, and Camzyos.
• Total global net sales for Q1 2025 were $11.2 billion, representing a 6% decline compared to the same period in 2024 due to generic competition for legacy products like Revlimid, Sprycel, and Pomalyst.